Bevacizumab as adjuvant therapy for lung cancer does not help patients over 65BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e2855 (Published 19 April 2012) Cite this as: BMJ 2012;344:e2855
- Bob Roehr
- 1Washington, DC
There is no substantial benefit for patients over 65 in adding bevacizumab (Avastin) to the standard treatment of carboplatin and paclitaxel for non-small cell lung cancer, a study shows (JAMA 2012;307:1593).
Bevacizumab gained that additional indication in 2006 based on a trial where two thirds of the patients were younger than 65, despite the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial